25 July 2023
N4 Pharma Plc
("N4 Pharma" or the "Company")
Patent Grant and Board Change
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, announces two operational updates.
Granting of further US patent
The University of Queensland has informed the Company that it has been notified by the US patent attorney of the granting of its further patent application in relation to Nuvec® in the United States.
N4 Pharma has licensed the exclusive worldwide rights to Nuvec® from the University of Queensland for therapeutic uses in humans and animals.
This granted patent in the US is for the composition of matter of the nanoparticle itself and will sit alongside the first US patent grant announced on 31 January 2022, which concerned how the nanoparticle is made using a broad description of the manufacturing process used by the Company.
Board Change
The Company announces that John Chiplin, currently Non-Executive Chairman, is retiring from the Board for personal reasons. Chris Britten, currently a Non-Executive Director of the Company, will assume the role of Non-Executive Chairman of N4 Pharma with effect from 1 August 2023.
The Company will initiate a search process to identify an additional Non-Executive Director and will provide an update as and when appropriate.
Nigel Theobald, Chief Executive Officer of the Company, commented:
"We are delighted to receive notification of this further patent grant for our licensed patent in this critical and influential market.
"The granting of this patent now means the patents in the US are on equal terms to those granted in other territories for both the particle itself and how it is made.
"On behalf of the Board, I would like to thank John for his contributions as Chairman of the Company over the last few years and we wish him all the best for the future."
Enquiries:
| N4 Pharma Plc Nigel Theobald, CEO Luke Cairns, Executive Director | Via IFC Advisory |
| | |
| SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Kasia Brzozowska (Corporate Finance) Vadim Alexandre/Rob Rees (Corporate Broking) | Tel: +44 (0)20 3470 0470 |
| | |
| Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker
IFC Advisory Limited Financial PR Graham Herring Zach Cohen | Tel: +44 (0)20 3657 0050
Tel: +44 (0)20 3934 6630 |
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.
N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre-clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
